ReviewFrontiers in microbiology2015
Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold.
Review in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 99 citations in OpenAlex.
- Functional Blood-Brain Barrier Crossing by Biomimetic M13 Phage Vectors for Targeted Neuronal Delivery.Advanced healthcare materials · 2026Article
- Bacteriophages in the Rhizosphere: Roles in Nutrient Cycling, Bacterial Community Structure, and Animal-Mediated Dispersal.MicrobiologyOpen · 2026Review
- Bacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies.Pathogens (Basel, Switzerland) · 2026Review
- M13 phage-based antigen presentation and immune response activation in vaccine development for animal infectious diseases.Frontiers in immunology · 2026Review
- Isolation of F-specificMethodsX · 2025Article
- Nanofilament immunotherapy induces potent antitumor vaccine responses.Journal for immunotherapy of cancer · 2025Article
- Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform.Annual review of virology · 2024Review
- Designing molecules: directing stem cell differentiation.Frontiers in bioengineering and biotechnology · 2024Review
- A modular phage vector platform for targeted photodynamic therapy of Gram-negative bacterial pathogens.iScience · 2023Article
- Review
- Cryo-electron microscopy of the f1 filamentous phage reveals insights into viral infection and assembly.Nature communications · 2023Article
- Review
- Bacteriophages as Biotechnological Tools.Viruses · 2023Review
- Alternative use of phage display: phage M13 can remain viable in the intestines of poultry without causing damage.AMB Express · 2022Article
- Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease.NPJ vaccines · 2022Article
- EGFR-Targeted Photodynamic Therapy.Pharmaceutics · 2022Review
- Expanding the chemical diversity of M13 bacteriophage.Frontiers in microbiology · 2022Review
- Gut Virome: Role and Distribution in Health and Gastrointestinal Diseases.Frontiers in cellular and infection microbiology · 2022Review
- A New Vaccination Method Based on Phage NgoΦ6 and Its Phagemid Derivatives.Frontiers in microbiology · 2022Article
- Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform.Nano research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the past 25 years, phage display technology has been an invaluable tool for studies of protein-protein interactions. However, the inherent biological, biochemical, and biophysical properties of filamentous bacteriophage, as well as the ease of its genetic manipulation, also make it an attractive platform outside the traditional phage display canon. This review will focus on the unique properties of the filamentous bacteriophage and highlight its diverse applications in current research. Particular emphases are placed on: (i) the advantages of the phage as a vaccine carrier, including its high immunogenicity, relative antigenic simplicity and ability to activate a range of immune responses, (ii) the phage's potential as a prophylactic and therapeutic agent for infectious and chronic diseases, (iii) the regularity of the virion major coat protein lattice, which enables a variety of bioconjugation and surface chemistry applications, particularly in nanomaterials, and (iv) the phage's large population sizes and fast generation times, which make it an excellent model system for directed protein evolution. Despite their ubiquity in the biosphere, metagenomics work is just beginning to explore the ecology of filamentous and non-filamentous phage, and their role in the evolution of bacterial populations. Thus, the filamentous phage represents a robust, inexpensive, and versatile microorganism whose bioengineering applications continue to expand in new directions, although its limitations in some spheres impose obstacles to its widespread adoption and use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.